- Home
- GXAI vs KZIA Comparison
GXAI vs KZIA Comparison
Compare GXAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- KZIA
- Stock Information
- Founded
- GXAI 2021
- KZIA 1994
- Country
- GXAI United States
- KZIA Australia
- Employees
- GXAI N/A
- KZIA N/A
- Industry
- GXAI
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- KZIA Health Care
- Exchange
- GXAI Nasdaq
- KZIA Nasdaq
- Market Cap
- GXAI 9.7M
- KZIA 5.1M
- IPO Year
- GXAI 2023
- KZIA 1999
- Fundamental
- Price
- GXAI $1.26
- KZIA $11.43
- Analyst Decision
- GXAI
- KZIA Strong Buy
- Analyst Count
- GXAI 0
- KZIA 2
- Target Price
- GXAI N/A
- KZIA $14.00
- AVG Volume (30 Days)
- GXAI 152.6K
- KZIA 705.9K
- Earning Date
- GXAI 08-12-2025
- KZIA 07-22-2025
- Dividend Yield
- GXAI N/A
- KZIA N/A
- EPS Growth
- GXAI N/A
- KZIA N/A
- EPS
- GXAI N/A
- KZIA N/A
- Revenue
- GXAI $27,740.00
- KZIA $1,549,158.00
- Revenue This Year
- GXAI N/A
- KZIA N/A
- Revenue Next Year
- GXAI N/A
- KZIA N/A
- P/E Ratio
- GXAI N/A
- KZIA N/A
- Revenue Growth
- GXAI 9987.27
- KZIA 248983.08
- 52 Week Low
- GXAI $1.00
- KZIA $2.86
- 52 Week High
- GXAI $7.50
- KZIA $40.75
- Technical
- Relative Strength Index (RSI)
- GXAI 41.89
- KZIA 76.27
- Support Level
- GXAI $1.30
- KZIA $5.86
- Resistance Level
- GXAI $1.65
- KZIA $11.34
- Average True Range (ATR)
- GXAI 0.10
- KZIA 1.11
- MACD
- GXAI -0.02
- KZIA 0.38
- Stochastic Oscillator
- GXAI 4.77
- KZIA 90.76
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.